Switzerland clears Pfizer/BioNTech vaccine for 12 to 15-year-olds
Adolescents have the same protection and side effects from the Pfizer/Biontech vaccine as 25-year-olds, studies have shown.
Keystone / Martial Trezzini
The Swiss health regulator Swissmedic has approved the use of the Pfizer/BioNTech vaccine for children aged as young as 12.
This content was published on
1 minute
swissinfo.ch/mga
Tests have shown the vaccine to be close to 100% effective at giving protection against Covid-19 for 12 to 15-year-olds, the agency said on FridayExternal link.
Children in this age group can be given two injections with the same dose as adults, resulting in the same immune response as 16- to 25-year-olds, trials have shown.
The range and severity of side effects proved to be no different between the two age groups: most frequently pain at the injection site, fatigue, headache, shivering, muscle pain, fever and joint pain lasting typically around three days and more pronounced after the second injection.
Last month, regulators in the United States approved the use of the Pfizer/BioNTech vaccine for children as young as 12.
The vaccine roll-out is accelerating in Switzerland. More than five million vaccination doses (Pfizer/BioNTech and Moderna) have been administered so far. Just over 22% of the population has been fully immunised, with another 15.4% having received one jab.
On Friday, the number of new recorded daily infections fell below 500 for the first time since the autumn.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
Bodycams: essential for good law enforcement, or a privacy risk?
Did you ever come across bodycams in your place of residence and if so, how do you think the use of bodycams alter the relationship between the public and (transport) police?
This content was published on
Swiss wheelchair racer Catherine Debrunner won the 5,000 metres to bring home Switzerland’s first gold medal at the Paralympics in Paris.
This content was published on
At the start of the year, the Swiss authorities were criticised for dragging their heels on vaccinations despite having ambitious targets. Drugs regulator Swissmedic took longer than many countries to approve new vaccines and when they arrived there were large discrepancies between the ability of cantons to administer doses at speed. But this week, Switzerland…
Covid-19: ‘No one will be safe until everyone is safe’
This content was published on
Swiss Solidarity, the humanitarian arm of the Swiss Broadcasting Corporation (SBC), has launched a new appeal to help those most in need.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.